Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHR | P35869 | 4/20 | 0.56 |
| ▸ | CMA1 | P23946 | 1/20 | 0.56 |
| ▸ | TYR | P14679 | 1/20 | 0.56 |
| ▸ | HTR6 | P50406 | 1/20 | 0.51 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.50 |
| ▸ | EGFR | P00533 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.46 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL94619 | 1.00 | AHR (0.56) | AHRCMA1TYRHTR6ENPP2 | |
| Hydrochloric Acid SCHEMBL7359009 | 0.98 | AHR (0.54) | AHRCMA1TYRHTR6ENPP2 | |
| Iodide SCHEMBL29022371 | 0.98 | AHR (0.54) | AHRCMA1TYRHTR6ENPP2 | |
| Bromide SCHEMBL27451953 | 0.98 | AHR (0.54) | AHRCMA1TYRHTR6ENPP2 | |
| Hydrochloric Acid SCHEMBL31197107 | 0.98 | AHR (0.54) | AHRCMA1TYRHTR6ENPP2 | |
| Propionic Acid SCHEMBL6598879 | 0.82 | ENPP2 (0.51) | AHRCMA1TYRHTR6ENPP2 | |
| SCHEMBL130519 | 0.81 | AHR (0.56) | AHRMEN1KMT2ACYP2A6EGFR | |
| SCHEMBL29560117 | 0.81 | AHR (0.56) | AHRMEN1KMT2ACYP2A6EGFR | |
| Hydrochloric Acid SCHEMBL3325397 | 0.79 | AHR (0.54) | AHRMEN1KMT2ACYP2A6EGFR | |
| Iodide SCHEMBL7361153 | 0.79 | AHR (0.54) | AHRMEN1KMT2ACYP2A6EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4676474-A2 | SYMMETRIC AMINOINDOLE-LINKED TRIAZINE FOR A DUAL EFFECT ON ALPHA-SYNUCLEIN AND TAU ISOFORM 2N4R FIBRILLIZATION | Purdue Research Foundation (US) | 2026-01-14 | — | — | EP | claimed |
| WO-2024206067-A2 | SYMMETRIC AMINOINDOLE-LINKED TRIAZINE FOR A DUAL EFFECT ON ALPHA-SYNUCLEIN AND TAU ISOFORM 2N4R FIBRILLIZATION | PURDUE RESEARCH FOUNDATION (US) | 2024-10-03 | — | — | WO | claimed |
| EP-3416948-B1 | INDACENE BEARING SULFONYLUREAS AS ANTI-INFLAMMATORY AGENTS | UNIV QUEENSLAND (AU) | 2024-07-24 | — | — | EP | claimed |
| EP-4676474-A2 | SYMMETRIC AMINOINDOLE-LINKED TRIAZINE FOR A DUAL EFFECT ON ALPHA-SYNUCLEIN AND TAU ISOFORM 2N4R FIBRILLIZATION | Purdue Research Foundation (US) | 2026-01-14 | — | — | EP | disclosed |
| US-12486300-B2 | Mithramycin oxime derivatives having increased selectivity and anti-cancer activity | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2025-12-02 | — | — | US | disclosed |
| WO-2024206067-A3 | SYMMETRIC AMINOINDOLE-LINKED TRIAZINE FOR A DUAL EFFECT ON ALPHA-SYNUCLEIN AND TAU ISOFORM 2N4R FIBRILLIZATION | PURDUE RESEARCH FOUNDATION (US) | 2024-11-07 | — | — | WO | disclosed |
| WO-2024206067-A2 | SYMMETRIC AMINOINDOLE-LINKED TRIAZINE FOR A DUAL EFFECT ON ALPHA-SYNUCLEIN AND TAU ISOFORM 2N4R FIBRILLIZATION | PURDUE RESEARCH FOUNDATION (US) | 2024-10-03 | — | — | WO | disclosed |
| EP-2277597-B2 | Reductive colour removal | HENKEL AG & CO KGAA (DE) | 2024-06-26 | — | — | EP | disclosed |
| WO-2024081692-A1 | MITHRAMYCIN OXIME DERIVATIVES HAVING INCREASED SELECTIVITY AND ANTI-CANCER ACTIVITY | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2024-04-18 | — | — | WO | disclosed |
| EP-4334303-A1 | COMPOUNDS FOR INHIBITING OR DEGRADING ITK, COMPOSITIONS, COMPRISING THE SAME METHODS OF THEIR MAKING AND METHODS OF THEIR USE | Nurix Therapeutics, Inc. (US) | 2024-03-13 | — | — | EP | disclosed |
| EP-4334302-A1 | COMPOUNDS FOR INHIBITING OR DEGRADING TARGET PROTEINS, COMPOSITIONS, COMPRISING THE SAME, METHODS OF THEIR MAKING, AND METHODS OF THEIR USE | Nurix Therapeutics, Inc. (US) | 2024-03-13 | — | — | EP | disclosed |
| CN-117136184-A | Aminopyrimidine compounds and methods of use thereof | 泰拉生物科学公司 | 2023-11-28 | — | — | CN | disclosed |
| US-20230132854-A1 | MITHRAMYCIN OXIME DERIVATIVES HAVING INCREASED SELECTIVITY AND ANTI-CANCER ACTIVITY | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION | 2023-05-04 | — | — | US | disclosed |
| US-20230047905-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | NOVARTIS PHARMA AG (CH) | 2023-02-16 | — | — | US | disclosed |
| EP-4103278-A1 | SMALL MOLECULE STING ANTAGONISTS | Curadev Pharma Pvt. Ltd. (IN) | 2022-12-21 | — | — | EP | disclosed |
| WO-2022235715-A1 | COMPOUNDS FOR INHIBITING OR DEGRADING ITK, COMPOSITIONS, COMPRISING THE SAME METHODS OF THEIR MAKING AND METHODS OF THEIR USE | NURIX THERAPEUTICS, INC. (US) | 2022-11-10 | — | — | WO | disclosed |
| WO-2022235698-A1 | COMPOUNDS FOR INHIBITING OR DEGRADING TARGET PROTEINS, COMPOSITIONS, COMPRISING THE SAME, METHODS OF THEIR MAKING, AND METHODS OF THEIR USE | NURIX THERAPEUTICS, INC. (US) | 2022-11-10 | — | — | WO | disclosed |
| US-11466045-B2 | Mithramycin oxime derivatives having increased selectivity and anti-cancer activity | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2022-10-11 | — | — | US | disclosed |
| EP-3998059-A9 | MILD PREPARATIONS AS CLEANING OR CARE COMPOSITIONS FOR REMOVING CARBOHYDRATES OR STAINS | Perfect Ideas GmbH (CH) | 2022-09-28 | — | — | EP | disclosed |
| EP-3998059-A1 | MILD PREPARATIONS AS CLEANING OR CARE COMPOSITIONS FOR REMOVING CARBOHYDRATES OR STAINS | Perfect Ideas GmbH (CH) | 2022-05-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12486300-B2 | Mithramycin oxime derivatives having increased selectivity and anti-cancer activity | TFAM, HSPE1, PRDX3 | AHR 2330/4885CMA1 4438/4885TYR 1018/4885 |
| US-11466045-B2 | Mithramycin oxime derivatives having increased selectivity and anti-cancer activity | HSPE1, TFAM, HMOX1 | AHR 1075/4885CMA1 3875/4885TYR 714/4885 |
| US-20230132854-A1 | MITHRAMYCIN OXIME DERIVATIVES HAVING INCREASED SELECTIVITY AND ANTI-CANCER ACTIVITY | TFAM, HSPE1, PRDX3 | AHR 2330/4885CMA1 4438/4885TYR 1018/4885 |
| US-20230047905-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | STING1, CGAS, IRF3 | AHR 2635/4885CMA1 596/4885TYR 1382/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.